Ocugen reports Q1 EPS (5c), consensus (6c)

Reports Q1 revenue $1.481M vs $1.014M last year. “All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologics License Application/Marketing Authorization Application filings in the next three years,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen (OCGN). “We remain steadfast in our mission to provide a one-time therapy for life to address considerable unmet medical needs that exist for millions of patients facing the terrifying prospect of losing their vison.”